FIG 9 .

HMO blocking of VLP binding to HBGAs. HMO inhibition assay of VLPs binding to HBGAs. (A) 2′FL showed little or no inhibition of VLP binding to PGM, and the IC₅₀s were not calculated. (B) 3FL showed dose-dependent inhibition. For type A VLPs (VLP2, VLP5, and VLP7), the 3FL IC₅₀s were 60 mM, 116 mM, and 82 mM, respectively, while for type B VLPs (VLP1, VLP4, and VLP11), the IC₅₀s were 6 mM, 6 mM, and 3 mM, respectively. Error bars show standard deviations.